ID
40797
Descrição
Study ID: 103933 Clinical Study ID: NKV103933 Study Title: A non-randomised, open label, two period cross-over study to determine the excretion balance and metabolic disposition of [14C]-GW679769, administered as single doses of an oral solution and an intravenous infusion to healthy male subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier:N/A Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: casopitant Trade Name: Rezonic,Zunrisa; Zunrisa,Rezonic Study Indication: Nausea and Vomiting, Chemotherapy-Induced Protocol ID: NKV103933 The eligibility to participate was determined during a screening visit within 21 days prior to first dosing day. The study consisted of two dosing periods, each consisting of predose visit, monitoring after dose administration and prior to discharge visit. Dosing periods were separated by a wash-out period of 43 days. The Drug Screening and Alcohol Breath Test form has to be filled in at screening and at both pre-dose treatment examinations.
Palavras-chave
Versões (1)
- 15/05/2020 15/05/2020 -
Titular dos direitos
GlaxoSmithKline
Transferido a
15 de maio de 2020
DOI
Para um pedido faça login.
Licença
Creative Commons BY-NC 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Study of Casopitant Pharmacokinetics in Healthy Males, NKV103933
Drug Screen, Alcohol Breath Test
- StudyEvent: ODM
Similar models
Drug Screen, Alcohol Breath Test
- StudyEvent: ODM
C0870078 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,3])
C0040223 (UMLS CUI [1,4])
C0002667 (UMLS CUI [1,2])
C0005064 (UMLS CUI [1,2])
C0006864 (UMLS CUI [1,2])
C0004745 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,2])